Crossmark

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?

Crossref DOI link: https://doi.org/10.1038/s41409-022-01616-7

Published Online: 2022-02-26

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khawaja, Fareed https://orcid.org/0000-0003-4424-283X
Chemaly, Roy F. https://orcid.org/0000-0002-0277-3088
License Information

Text and Data Mining valid from 2022-02-26

Version of Record valid from 2022-02-26
More Information

Article History

Received: 18 January 2022

Revised: 4 February 2022

Accepted: 9 February 2022

First Online: 26 February 2022

Competing interests

: RFC serves a scientific consultant/adviser for Merck, Ansun Biopharma, Takeda/Shire, Oxford Immunotec, ADMA Biologics, Pulmotec, Enanta, ReViral, and Genentech, and received research funding from Merck, Takeda/Shire, Oxford Immunotec, AiCuris, Ansun Biopharma, Viracor, Karius, Genentech, and Janssen. FK has none to report.

Document is current

Any future updates will be listed below